StockNews.AI
ALT
StockNews.AI
12 days

Altimmune, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before October 6, 2025 to Discuss Your Rights – ALT

1. ALT stock plunged 53.2% following negative trial results on June 26, 2025. 2. Company missed statistical significance in primary endpoint of Phase 2b trial. 3. Class action lawsuit filed over alleged misleading expectations from ALT. 4. Shareholders encouraged to register for involvement in legal action. 5. The deadline to seek lead plaintiff status is October 6, 2025.

5m saved
Insight
Article

FAQ

Why Very Bearish?

The significant stock drop signals strong market disapproval and investor unease, reminiscent of other biotech sector failures after negative trial outcomes.

How important is it?

The allegations of misleading information could greatly influence investor confidence and stock performance.

Why Short Term?

Immediate legal ramifications and investor sentiment are likely to keep the stock depressed for the foreseeable future.

Related Companies

MMLPAMGNVRTX
NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT). Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/altimmune-inc-loss-submission-form-2/?id=159976&from=3 CLASS PERIOD: August 10, 2023 to June 25, 2025 ALLEGATIONS: According to the complaint, on June 26, 2025, Altimmune published a press release announcing topline results from the IMPACT Phase 2b MASH trial of Pemvidutide in the Treatment of MASH. While defendants had continuously provided inflated expectations ahead of these results, the analysis showed a pointed failure by the Company to achieve statistical significance in its analysis of the fibrosis reduction primary endpoint in its IMPACT Phase 2b MASH trial. In particular, while a positive trend in fibrosis improvement was observed, statistical significance was not met due to a higher-than-expected placebo response. When questioned about this concerning miss, defendants answered indifferently, attributing this result to the Phase 2 nature of the trial and stated that Altimmune was hoping for better results following the Phase 3 trial. Following this news, the price of Altimmune’s common stock declined dramatically. From a closing market price of $7.71 per share on June 25, 2025, Altimmune’s stock price fell to $3.61 per share on June 26, 2025, a decline of 53.2% in the span of just a single day. DEADLINE: October 6, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/altimmune-inc-loss-submission-form-2/?id=159976&from=3 NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of ALT during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is October 6, 2025. There is no cost or obligation to you to participate in this case. WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Email: dg@securitiesclasslaw.comPhone: (646) 453-8903

Related News